Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Acute Myeloid Leukemia: early-phase trial registry
159 of 307 indexed Acute Myeloid Leukemia trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #26 of 28,707 conditions by registered trial count.
307 US clinical trials · 159 currently recruiting · #26 of 28,707 conditions by registered trial count
Acute Myeloid Leukemia: 307 US clinical trials tracked, 159 recruiting.
Acute Myeloid Leukemia is the subject of 307 registered US clinical trials on ClinicalTrials.gov, 159 of them currently open to new participants. 13 are in Phase 3-4 (later-stage) and 265 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 38 of these trials.
Enrollment posture brief
Registry condition acute-myeloid-leukemia
OPEN 159 | RECR 52% | LATE 13 | EARLY 265 | RANK #26 | SPON 38
Volume-matched condition peers
Nearest open-share peer: Aortic Stenosis (52% recruiting · 27 trials)
Acute Myeloid Leukemia lists 159 open slots (52% of 307 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Acute Myeloid Leukemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Acute Myeloid Leukemia is recruiting above its size-band peers.
159 of 307 indexed trials (51.8%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Acute Myeloid Leukemia trials is spread across many organizations.
M.D. Anderson Cancer Center accounts for 38 of 307 trials (12.4%). 128 distinct sponsors appear on at least one study for this condition label.
-
Most Acute Myeloid Leukemia trials plan to enrol fewer than 100 people.
Median target enrolment is 49 among the 307 trials that report a genuine target (sentinel values excluded). 223 of those (72.6%) plan for fewer than 100 participants.
-
Acute Myeloid Leukemia research is mostly interventional.
290 interventional and 17 observational studies make up this index (94.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
307 total, page 6 of 7
A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Pfizer
NCT01546038
IV Busulfan With Allo-BMT: Study for Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT00469144
A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML
Seagen
NCT00528333
Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
NCT01420926
Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers
Roswell Park Cancer Institute
NCT04484532
Clinical Factors Associated With the Development of Severe Sepsis in Patients Being Treated for Acute Myeloid Leukemia
Ohio State University
NCT00806325
A Study of Clofarabine for Older Patients With Newly Diagnosed Acute Myelogenous Leukemia (AML) (CLASSIC II)
Genzyme, a Sanofi Company
NCT00373529
Study of Voreloxin (Vosaroxin) in Older Patients With Untreated Acute Myeloid Leukemia
Sunesis Pharmaceuticals
NCT00607997
Safety and Tolerability Study of Voreloxin and Cytarabine Combination in Acute Myeloid Leukemia in Humans
Sunesis Pharmaceuticals
NCT00541866
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
Seagen
NCT01461538
A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia
Astellas Pharma Global Development
NCT02236013
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
Fred Hutchinson Cancer Center
NCT00723099
Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT00469014
Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
National Cancer Institute (NCI)
NCT01238211
Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML
Novartis Pharmaceuticals
NCT01883362
CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT02286726
Shotgun Sequencing in Diagnosing Febrile Neutropenia in Patients With Acute Myeloid Leukemia
Stanford University
NCT02856204
Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome
Aileron Therapeutics
NCT02909972
Study of Bexarotene in Patients With Acute Myeloid Leukemia
Abramson Cancer Center at Penn Medicine
NCT00316030
Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)
H. Lee Moffitt Cancer Center and Research Institute
NCT00831766
INCB018424 in Patients With Advanced Hematologic Malignancies
M.D. Anderson Cancer Center
NCT00674479
Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML)
University of California, San Diego
NCT00766116
Ascorbic Acid Levels in MDS, AML, and CMML Patients
Van Andel Research Institute
NCT03526666
Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
National Cancer Institute (NCI)
NCT02029950
T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts
Baylor College of Medicine
NCT00368355
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia
Cellerant Therapeutics
NCT01297543
Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT
University of Virginia
NCT04629430
HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies
St. Jude Children's Research Hospital
NCT00145626
A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML)
Hoffmann-La Roche
NCT02892318
Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML
Traws Pharma
NCT00854945
A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia
Kartos Therapeutics
NCT02016729
Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Patients
Arog Pharmaceuticals
NCT02400255
Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients
Arog Pharmaceuticals
NCT02400281
Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT01700673
NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid Diseases
Masonic Cancer Center, University of Minnesota
NCT01370213
Off-the-shelf NK Cells + SCT for Myeloid Malignancies
M.D. Anderson Cancer Center
NCT05115630
IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation
Massachusetts General Hospital
NCT03515512
Sorafenib Maintenance Therapy for Patients With AML After Allogeneic Stem Cell Transplant
Massachusetts General Hospital
NCT01398501
Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation
Stanford University
NCT03734601
A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML
H. Lee Moffitt Cancer Center and Research Institute
NCT02403310
Low-Dose Daunorubicin in Relapsed/Refractory Acute Leukemia
Tara Lin
NCT02914977
CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma
Robert Lowsky
NCT02424968
LY3214996 in Patients With AML Who Are Not Candidates for Standard Therapy
Dana-Farber Cancer Institute
NCT04081259
KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia
University of Colorado, Denver
NCT04914845
Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy
Robert Redner, MD
NCT03839446
Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant
Sherif S. Far
NCT01720264
Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS
Masonic Cancer Center, University of Minnesota
NCT04055844
Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies
Case Comprehensive Cancer Center
NCT02129582
A Study of E7820 in People With Bone Marrow (Myeloid) Cancers
Memorial Sloan Kettering Cancer Center
NCT05024994
Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers
ViaCell
NCT00089596
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 160 |
| Phase 2 | 105 |
| Phase 3 | 12 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Acute Myeloid Leukemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Acute Myeloid Leukemia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Acute Myeloid Leukemia page
307 registered trials, 159 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 159 Acute Myeloid Leukemia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Acute Myeloid Leukemia trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Acute Myeloid Leukemia condition card totals 307 registered trials; most-linked intervention Venetoclax; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.